本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Lyell Immunopharma, Inc.

0.4612
-0.0088-1.87%
盤後0.46120.00000.00%16:10 EDT
成交量:49.04萬
成交額:22.91萬
市值:1.36億
市盈率:-0.35
高:0.4850
開:0.4700
低:0.4549
收:0.4700
資料載入中...
2024/05/02

SEC問詢函

Form CORRESP - Correspondence
2024/02/29

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/02/29

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/02/28

重要事件披露

Form 8-K - Current report
2024/02/14

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2023/11/21

重要事件披露

Form 8-K - Current report
2023/11/08

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/08

重要事件披露

Form 8-K - Current report
2023/09/11

重要事件披露

Form 8-K - Current report
2023/08/15

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2023/08/15

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2023/08/15

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2023/08/15

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2023/08/08

重要事件披露

Form 8-K - Current report
2023/08/08

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/07/17

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2023/07/17

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2023/07/17

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2023/07/17

關聯方擬減持公告

Form 144 - Report of proposed sale of securities